Produção Nacional
Revisado por pares
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011; Massachusetts Medical Society; Volume: 366; Issue: 2 Linguagem: Inglês
10.1056/nejmoa1113216
ISSN1533-4406
AutoresJosé Baselga, Javier Cortés, Sung‐Bae Kim, Seock‐Ah Im, Roberto Hegg, Young‐Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pieńkowski, Adam Knott, Emma Clark, Mark Benyunes, Graham Ross, Sandra M. Swain,
Tópico(s)Peptidase Inhibition and Analysis
ResumoThe anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer.
Referência(s)